Klin Farmakol Farm. 2003;17(1):12-16

Hodnotenie rizika liekov vo vzťahu k jeho percepcii

Milan Kriška1,2, Juraj Payer3, Igor Novák4, Daniela Ježová5
1 Farmakologický ústav Lekárskej fakulty UK, Bratislava
2 Nemocnica s poliklinikou Považská Bystrica
3 I. interná klinika FN a LFUK, Bratislava
4 Ely Lilly S. A. Bratislava
5 Endokrinologický ústav SAV Bratislava

Práca sa zaoberá hodnotením rizika liekov s dôrazom na skupinu psychofarmák. Autori hodnotia percepciu rizika v súvislosti s faktormi ovplyvňujúcimi preskripciu liekov a so systémom monitorovania nežiaducich účinkov v medicínskej praxi. Poukazujú na nízku frekvenciu hlásením nežiaducich účinkov v SR , kde pretrváva v sponntánnom monitorovaní veľmi nízka aktivita psychiatrov a neurológov. Analyzujú niektoré príčiny nízkej percepcie rizika liekov a hľadajú možnosti prevencie.

Keywords: psychopharmaceuticals, pharmacovigilance, Drug adverse event report, drug risk, prevention.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kriška M, Payer J, Novák I, Ježová D. Hodnotenie rizika liekov vo vzťahu k jeho percepcii. Klin Farmakol Farm. 2003;17(1):12-16.

Práca sa zaoberá hodnotením rizika liekov s dôrazom na skupinu psychofarmák. Autori hodnotia percepciu rizika v súvislosti s faktormi ovplyvňujúcimi preskripciu liekov a so systémom monitorovania nežiaducich účinkov v medicínskej praxi. Poukazujú na nízku frekvenciu hlásením nežiaducich účinkov v Slovenskej republike, kde pretrváva v spontánnom monitorovaní veľmi nízka aktivita psychiatrov a neurológov. Analyzujú niektoré príčiny nízkej percepcie rizika liekov a hľadajú možnosti prevencie.

Kľúčové slová

psychofarmaká, farmakovigilancia, hlásenie NÚL, riziko liekov, prevencia.

Drug risks evaluation in connection with theirs perception

An article concerns on drugs risks evaluation with emphasis to psychopharmaceuticals. Authors evaluate perception of risk connected with drug-s prescription influencing factors and a system of adverse events monitoring in medical practice. They refer to low adverse events reports level in Slovak Republic, where low activity of psychiatrists and neurologists persists in spontaneous monitoring. Authors analyse some reasons for low perception of drug risks and seek for possibilities of prevention.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. van Boxtel Ch J, Santoso B, Edwards I R, eds. Drug benefits and risk: international textbook of clinical pharmacology. Chichester UK: John Wiley & Sons Ltd, 2001: 717.
    2. Mamdani M, Herrmann N, Austin P. Prevalence of antidepressant use among older people: population-based observations. J Am Geriat Soc 1999; 47: 1350-1353. Go to original source... Go to PubMed...
    3. Foltán V, Čintala J, eds. Lieková politika a jej reflexia v spotrebe liekov na Slovensku. Bratislava ŠUKL 2001: 98.
    4. Gajdošík J. Farmakoterapeutické rozhodovanie praktického lekára pre dospelých. Slovenský lekár 2002; 26: 438-442.
    5. Anonymus. A review of drug-induced psychiatric effects (Part 6). Worst Pills - Best Pills News 1999; 5: 38.
    6. Anonymus. Drug induced psychiatric symptoms (Part 2). Worst Pills - Best Pills News 2002; 8: 81-84.
    7. Sutcliffe H, Macdonald L. Adverse drug reaction reporting - 2000 (Part 2). Can Adverse Drug React Newsl 2001; 11: 3.
    8. Kořínková V, Ježová D. Antidepresíva. In: Kriška M a kol. Memorix klinickej farmakológie. Bratislava SAP 2002: 707-732.
    9. Uppsala Monitoring Centre, WHO collaborating centre for international drug monitoring Uppsala, Sweden.
    10. Hőschl C, Libiger J, Švestka J. Psychiatrie. Tigris 2002: 442.
    11. Zbierka zákonov: Zákon o lieku: zákon č. 140/1998 Z.z. o liekoch a zdravotníckych pomôckach v znení neskorších predpisov.
    12. Leape LL. Reporting of adverse events. N Engl J Med 2002; 347: 1633-1638. Go to original source... Go to PubMed...
    13. Kořínková V. Neuroleptiká. In: Kriška M a kol eds. Riziko liekov v medicínskej praxi. Bratislava SAP 2000: 391-409.
    14. Caligiuri MP, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly. Drugs&Aging 2000; 17: 363-384. Go to original source... Go to PubMed...
    15. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 2000; 23: 215-227. Go to original source... Go to PubMed...
    16. Monitorovací systém Lex-Sys. Novartis.
    17. Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine. CNS Drugs 2002; 16: 317-324. Go to original source... Go to PubMed...
    18. Meaney AM, O´Keane V. Prolactin and schizophrenia : clinical consequences of hyperprolactinaemia. Life Sciences 2002; 71: 979-992. Go to original source... Go to PubMed...
    19. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Assotiation of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-566. Go to original source... Go to PubMed...
    20. Ondrejkovičová A, Payer J, Korcsog P, kriška M. Diferenciálná diagnostika hyperprolaktynémie se zameraním na antipsychotckú liečbu. Lek. obz. 2003; 52: 61-64.
    21. Rawlins M D and Thompson JW. Pathogenesis of adverse drug reactions. In: Textbook of adverse drug reactions (Ed. Davies, D. M.) Oxford Univ Press 1977: 10.
    22. Davies DM, Ferner RE, de Glanoville H. eds. Textbook of adverse drug reactions. Oxford Univ. Press 1977: 971.
    23. Strom BL. Pharmacoepidemiology. Third Ed, New York, John Wiley &Sons, Ltd 2000: 874.
    24. Bates DV, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implication for prevention. JAMA 1995; 274: 29-34. Go to original source... Go to PubMed...
    25. Bongard V, Menard-Tache S, Bagheri H, Kabiri K, Lapeyre-Mestre M, Montastruc JL. Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol 2002; 54: 433-436. Go to original source... Go to PubMed...
    26. Neuten CI, Walop W. Where is the epidemiology in pharmacovigilance? Pharmacoepid Drug Safety 2000; 9: 337-340. Go to original source...
    27. Jones JK. Pharmacogenetics and pharmacoepidemiology. Pharmacoepid Drug Safety 2001; 10: 457-461. Go to original source... Go to PubMed...
    28. Perlík F, Slanař O, Šmíd M, Petráček J. Attitude of Czech physicians to adversee drug reaction reporting. Eur J Clin Pharmacol 2002; 58: 367-369. Go to original source... Go to PubMed...
    29. Meyboom RHB. The case for good pharmacovigilance practice. Pharmacoepid Drug Safety 2000; 9: 335-336. Go to original source...
    30. Bakstrom M, Mjordal MM, Dahlquist R. Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepid Drug Safety 2002; 11: 647-650. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.